How to Get Farxiga (Dapagliflozin) in New Mexico

Who Can Prescribe Farxiga in New Mexico

Any prescriber holding an active New Mexico license and DEA registration (where applicable) can write a Farxiga prescription. That group includes MDs, DOs, nurse practitioners, and physician assistants.

New Mexico grants full practice authority to nurse practitioners, meaning NPs can independently evaluate, diagnose, and prescribe dapagliflozin without a supervising physician. PAs in New Mexico prescribe under a collaborative practice agreement with a licensed physician, but the agreement does not restrict their ability to prescribe non-controlled medications like Farxiga. For patients in rural counties such as Catron, Harding, or De Baca, an NP at a federally qualified health center may be the most accessible prescriber.

Endocrinologists, cardiologists, nephrologists, and primary care providers all prescribe dapagliflozin regularly. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as second-line therapy for type 2 diabetes when atherosclerotic cardiovascular disease, heart failure, or CKD is present. A primary care physician comfortable with these guidelines can initiate therapy without a specialist referral.

Telehealth Prescribing in New Mexico

New Mexico permits telehealth prescribing for non-controlled medications, and Farxiga falls squarely into that category. A patient anywhere in the state can complete a synchronous video visit with a provider licensed in New Mexico, receive a prescription electronically, and have it sent to a local pharmacy the same day.

The New Mexico Medical Board requires that telehealth encounters meet the same standard-of-care benchmarks as in-person visits per NM Administrative Code 16.10.8. That means the provider must review medical history, current medications, and relevant lab work before prescribing. Most telehealth platforms allow patients to upload recent lab results or order new labs through a partnered draw site. Quest Diagnostics operates locations in Albuquerque, Las Cruces, and Santa Fe. Labcorp has a smaller footprint in the state but accepts mobile phlebotomy requests in some ZIP codes.

Telehealth removes a barrier that matters in New Mexico specifically. The state ranks 36th in physician density, with only 219 active primary care physicians per 100,000 residents in metro areas and far fewer in rural counties. For patients in southeastern or northwestern New Mexico, a video visit can cut weeks off the time to first prescription.

Required Labs Before Starting Farxiga

Prescribers in New Mexico follow the same lab requirements as those in any other state. The FDA-approved prescribing information for Farxiga specifies that renal function should be assessed before initiation.

A standard pre-Farxiga lab panel includes:

• eGFR (estimated glomerular filtration rate). Farxiga is approved for patients with an eGFR of 25 mL/min/1.73 m² or higher for heart failure and CKD indications. For the type 2 diabetes indication, the glycemic benefit diminishes below an eGFR of 45 mL/min/1.73 m².
• HbA1c. Baseline glycated hemoglobin helps the prescriber set a treatment target and decide whether dapagliflozin monotherapy or combination therapy is appropriate.
• Basic metabolic panel (BMP). This captures serum potassium, sodium, bicarbonate, and creatinine. SGLT2 inhibitors can cause volume depletion and, rarely, euglycemic diabetic ketoacidosis (euDKA), so baseline electrolytes matter.
• Urinalysis. Some providers order a urinalysis to check for active urinary tract infection, which is a relative precaution given the increased UTI risk with SGLT2 inhibitors.

Labs drawn within the prior 90 days are typically accepted. Results from a New Mexico hospital, clinic, or national lab chain can be uploaded to the prescribing provider electronically.

New Mexico Medicaid and Farxiga Coverage

New Mexico Medicaid does not currently cover Farxiga. The state's Medicaid managed care organizations (Centennial Care 2.0 plans administered by Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and Western Sky Community Care) list dapagliflozin as non-preferred or excluded from their formularies.

This coverage gap creates a real cost problem. The wholesale acquisition cost of brand-name Farxiga is approximately $18.30 per tablet, or roughly $549 per 30-day supply. Without coverage, few patients can sustain that out-of-pocket spend.

Options for Medicaid-enrolled patients:

1. Exception request. A prescriber can submit a prior authorization with clinical justification citing the DAPA-HF trial, which showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin 10 mg versus placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [1]. For patients with heart failure and reduced ejection fraction, this evidence may support a medical necessity override.
2. AstraZeneca patient assistance. AstraZeneca's Farxiga Savings Program offers eligible uninsured or underinsured patients the drug at no cost. Income thresholds apply.
3. 503A compounding. A licensed 503A pharmacy in New Mexico can compound dapagliflozin if the prescriber writes the prescription specifying compounding. Compounded versions may cost 40% to 60% less than brand, though availability fluctuates with API (active pharmaceutical ingredient) supply.

Commercial Insurance and Prior Authorization

Most commercial plans in New Mexico require prior authorization before covering Farxiga. Blue Cross Blue Shield of New Mexico, Presbyterian, Molina, and Cigna all classify dapagliflozin as a non-preferred brand SGLT2 inhibitor with step therapy requirements.

A typical prior authorization for Farxiga in New Mexico requires the following documentation:

• Confirmed diagnosis of type 2 diabetes (ICD-10 E11.x), heart failure (I50.x), or chronic kidney disease (N18.x)
• Documentation that the patient has tried and failed, or has a contraindication to, at least one preferred SGLT2 inhibitor (usually empagliflozin/Jardiance)
• Recent HbA1c and eGFR values
• Prescriber's clinical rationale, ideally citing guideline-concordant evidence

The turnaround for standard prior authorization in New Mexico is 5 to 7 business days for commercial plans. Expedited (urgent) requests must be processed within 72 hours per New Mexico Office of Superintendent of Insurance regulations. If denied, the patient has the right to an internal appeal and, subsequently, an external review through an independent review organization.

The DAPA-CKD trial demonstrated a 39% reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [2]. Citing this trial in the prior authorization letter strengthens the case for patients with CKD stages 2 through 4.

Pharmacy Access Across New Mexico

New Mexico has approximately 380 licensed retail pharmacies. Walgreens, CVS, and Walmart pharmacies stock Farxiga in most metro locations including Albuquerque, Santa Fe, Las Cruces, and Rio Rancho. Independent pharmacies in smaller cities like Roswell, Farmington, and Gallup may need to order the drug from their wholesaler, which typically adds 1 to 2 business days.

Mail-order pharmacy is a practical option for patients in remote areas. Express Scripts, CVS Caremark, and OptumRx all ship to New Mexico addresses, and many plans offer a 90-day supply at a reduced copay through mail order. A 90-day Farxiga supply through mail order can save $30 to $60 in copays compared to three monthly fills at a retail pharmacy, depending on the plan's benefit design.

For patients without insurance, GoodRx and RxSaver discount cards bring the cash price of Farxiga 10 mg (30 tablets) to approximately $470 to $520 at Albuquerque-area pharmacies. That is still a significant cost, which is why the AstraZeneca savings card or 503A compounding routes are worth exploring.

503A Compounding Pharmacies in New Mexico

New Mexico licenses 503A compounding pharmacies under the New Mexico Board of Pharmacy. These pharmacies can compound dapagliflozin from bulk API when a patient-specific prescription is provided by a licensed prescriber.

Several 503A pharmacies in New Mexico ship statewide. Compounded dapagliflozin is typically dispensed as oral capsules rather than tablets, and the pharmacy can adjust the dose (5 mg or 10 mg) to match the prescriber's order. Pricing for a 30-day supply of compounded dapagliflozin ranges from $180 to $320, a meaningful discount versus the brand product.

A few things to verify before using a 503A pharmacy:

• Confirm the pharmacy holds a current New Mexico Board of Pharmacy compounding license.
• Ask whether the pharmacy sources its dapagliflozin API from an FDA-registered supplier.
• Confirm beyond-use dating (BUD) and storage requirements. Compounded oral solid dosage forms typically carry a 180-day BUD per USP 795 standards.
• Understand that compounded drugs are not FDA-approved and are not AB-rated equivalents to brand Farxiga.

Transferring a Farxiga Prescription to New Mexico

If a patient moves to New Mexico or switches pharmacies, the prescription transfer process is straightforward. Federal and New Mexico state law permit the transfer of non-controlled prescription medications between licensed pharmacies.

The patient can call the new pharmacy in New Mexico and provide the name, phone number, and prescription number from the original (transferring) pharmacy. The receiving pharmacist contacts the originating pharmacy to complete the transfer. This process usually takes 15 to 30 minutes. Electronic prescription transfers through shared pharmacy networks (e.g., within the CVS or Walgreens chain) can happen even faster.

For patients coming from another state, the prescribing provider must be verified, but the transfer itself is not restricted by state lines for non-controlled medications. If the original prescription has no remaining refills, the patient will need a new prescription from a New Mexico-licensed provider.

Timeline from First Visit to First Dose

The path from initial consultation to first dose of Farxiga in New Mexico typically takes 7 to 14 days, broken down as follows:

• Day 1. Telehealth or in-person consultation. Provider reviews history, orders labs.
• Days 2 to 4. Patient completes lab draw. Results return within 24 to 48 hours for standard panels.
• Day 4 to 5. Provider reviews labs, writes prescription, submits prior authorization if required.
• Days 5 to 12. Prior authorization processing (5 to 7 business days for standard review).
• Day 12 to 14. Prescription filled and picked up, or shipped via mail order.

Patients paying cash or using an AstraZeneca savings card can skip the prior authorization step entirely, compressing the timeline to 4 to 7 days. Telehealth platforms that partner with in-network labs can sometimes complete the entire process within 5 business days.

Cost-Saving Strategies Specific to New Mexico

New Mexico residents have several avenues to reduce out-of-pocket spending on Farxiga:

AstraZeneca Savings Card. Commercially insured patients may pay as little as $0 per fill, with a maximum annual benefit. The card is not valid for government-insured patients (Medicare, Medicaid, Tricare, VA).

AstraZeneca Patient Assistance Program (AZ&Me). Uninsured patients with household income at or below 400% of the federal poverty level may receive Farxiga at no cost. In 2026, that threshold is approximately $62,400 for a single individual.

New Mexico Pharmaceutical Assistance Program. The state does not operate a standalone pharmaceutical assistance program, but the New Mexico Aging and Long-Term Services Department can connect Medicare-eligible patients with Extra Help (Low-Income Subsidy) applications for Part D plans that cover Farxiga.

340B pricing. Patients who receive care at 340B-eligible entities (federally qualified health centers, Indian Health Service facilities, disproportionate share hospitals) may access Farxiga at significantly reduced cost. New Mexico has 16 FQHC organizations with dozens of sites, many in underserved areas. The HRSA 340B Drug Pricing Program governs eligibility.

Generic dapagliflozin. As of mid-2026, no FDA-approved generic dapagliflozin is available in the United States. AstraZeneca's patent protections extend through the late 2020s, though paragraph IV challenges have been filed.

Clinical Evidence Supporting Dapagliflozin Access

The evidence base for dapagliflozin is built on three large outcome trials that collectively enrolled over 21,000 patients.

DAPA-HF (N=4,744). Published in the New England Journal of Medicine in 2019, this trial randomized patients with heart failure and ejection fraction of 40% or less to dapagliflozin 10 mg or placebo. The primary composite endpoint (worsening heart failure or cardiovascular death) occurred in 16.3% of the dapagliflozin group versus 21.2% of the placebo group (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [1]. The benefit was consistent regardless of whether the patient had type 2 diabetes.

DAPA-CKD (N=4,304). This trial enrolled patients with CKD (eGFR 25 to 75 mL/min/1.73 m²) and demonstrated a 39% reduction in the primary composite renal endpoint with dapagliflozin versus placebo (HR 0.61; P<0.001) [2]. The trial was stopped early for efficacy. The DAPA-CKD results led to the expanded FDA indication for CKD regardless of diabetes status.

DECLARE-TIMI 58 (N=17,160). This cardiovascular outcomes trial in type 2 diabetes showed that dapagliflozin reduced hospitalization for heart failure by 27% compared with placebo (HR 0.73; 95% CI 0.61 to 0.88) [3]. It did not meet its primary endpoint of superiority for major adverse cardiovascular events (MACE), but the heart failure signal was strong and clinically meaningful.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline recommends SGLT2 inhibitors for patients with CKD and an eGFR of 20 mL/min/1.73 m² or higher, stating: "We recommend treating patients with CKD with an SGLT2 inhibitor" (evidence level 1A) [4].

The American Heart Association and American College of Cardiology 2022 heart failure guideline list SGLT2 inhibitors as a class I recommendation for HFrEF, noting: "In patients with HFrEF, an SGLT2 inhibitor is recommended to reduce hospitalization for heart failure and cardiovascular mortality" [5].